The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study

Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated that nintedanib reduced functional disease progression also in subjects with non-IPF progressive fibrosing interstitia...

Full description

Bibliographic Details
Main Authors: Paolo Cameli, Valerio Alonzi, Miriana d’Alessandro, Laura Bergantini, Elena Pordon, Marco Guerrieri, Rosa Metella Refini, Piersante Sestini, Elena Bargagli
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Biomedicines
Subjects:
nintedanib
real-world effectiveness
idiopathic pulmonary fibrosis
familial pulmonary fibrosis
mortality
Online Access:https://www.mdpi.com/2227-9059/10/8/1973

Similar Items

Similar Items